# EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Source: https://onco.cc/trials/nct06486142/  
OnCo record `nct06486142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Afatinib, Dacomitinib and Osimertinib in Non-small-cell lung cancer, run by Region Skane, now recruiting.

## Summary

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study is a phase 3 interventional study registered as NCT06486142 by Region Skane, with 200 participants planned, started 2022-09-21 and due to reach its primary completion in 2028-09. Interventions recorded: Afatinib/Dacomitinib, Osimertinib. Conditions recorded: Non-Small Cell Lung Cancer.

Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06486142
- Phase: 3
- Setting: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
- Sponsor: Region Skane
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06486142: https://clinicaltrials.gov/study/NCT06486142

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Afatinib](https://onco.cc/drugs/afatinib/), [Dacomitinib](https://onco.cc/drugs/dacomitinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06486142.json